Gauge Group and Topology Change

The purpose of this study is to examine the effect of topology change in the initial universe. In this study, the concept of $G$-cobordism is introduced to argue about the topology change of the manifold on which a transformation group acts. This $G$-manifold has a fiber bundle structure if the group action is free and is related to the spacetime in Kaluza-Klein theory or Einstein-Yang-Mills system. Our results revealed that fundamental processes of compactification in $G$-manifolds. In these processes, the initial high symmetry and multidimensional universe changes to present universe by the mechanism which lowers the dimensions and symmetries.Comment: 8 page

One-loop Evolution of a Rolling Tachyon

We study the time evolution of the one-loop diagram in Sen's rolling tachyon background. We find that at least in the long cylinder case they grow rapidly at late time, due to the exponential growth of the timelike oscillator terms in the boundary state. This can also be interpreted as the virtual open string pair creation in the decaying brane. This behavior indicates a breakdown of this rolling tachyon solution at some point during the evolution. We also discuss the closed string emission from this one-loop diagram, and the evolution of a one-loop diagram connecting a decaying brane to a stable brane, which is responsible for the physical open string creation on the stable brane.Comment: 21 pages, 2 figures; v2: references added, comments revised in various places; v3: footnotes 7&8 added, revised version to appear in PR

On the origin of thermal string gas

We investigate decaying D-branes as the origin of the thermal string gas of string gas cosmology. We consider initial configurations of low-dimensional branes and argue that they can time evolve to thermal string gas. We find that there is a range in the weak string coupling and fast brane decay time regimes, where the initial configuration could drive the evolution of the dilaton to values, where exactly three spacelike directions grow large.Comment: 16 pages, 4 figures, v2: references adde

Rolling Tachyon Solution in Vacuum String Field Theory

We construct a time-dependent solution in vacuum string field theory and investigate whether the solution can be regarded as a rolling tachyon solution. First, compactifying one space direction on a circle of radius R, we construct a space-dependent solution given as an infinite number of *-products of a string field with center-of-mass momentum dependence of the form e^{-b p^2/4}. Our time-dependent solution is obtained by an inverse Wick rotation of the compactified space direction. We focus on one particular component field of the solution, which takes the form of the partition function of a Coulomb system on a circle with temperature R^2. Analyzing this component field both analytically and numerically using Monte Carlo simulation, we find that the parameter b in the solution must be set equal to zero for the solution to approach a finite value in the large time limit x^0\to\infty. We also explore the possibility that the self-dual radius R=\sqrt{\alpha'} is a phase transition point of our Coulomb system.Comment: 39 pages, 17 figures, v3: references adde

Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report

<p>Abstract</p> <p>Introduction</p> <p>A combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has been used to control proteinuria, following initial demonstration of its efficacy. However, recently concerns about the safety of this therapy have emerged, prompting several authors to urge for caution in its use. In the following case report, we describe the occurrence of a serious and unexpected adverse drug reaction after administration of a combination of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers to a patient with nephrotic syndrome and liver cirrhosis with severe portal hypertension.</p> <p>Case presentation</p> <p>We administered this combination therapy to a 40-year-old Caucasian man with liver cirrhosis in our Hepatology Clinic, given the concomitant presence of glomerulopathy associated with severe proteinuria. While the administration of one single drug appeared to be well-tolerated, our patient developed severe acute encephalopathy after the addition of the second one. Discontinuation of the therapy led to the disappearance of the side-effect. A tentative rechallenge with the same drug combination led to a second episode of acute severe encephalopathy.</p> <p>Conclusion</p> <p>We speculate that this adverse reaction may be directly related to the effect of angiotensin II on the excretion of blood ammonia. Therefore, we suggest that patients with liver cirrhosis and portal hypertension are at risk of developing clinically relevant encephalopathy when angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker combination therapy is administered, thus indicating the need for a careful clinical follow-up. In addition, the incidence of this serious side-effect should be rigorously evaluated in all patients with liver cirrhosis administered with this common treatment combination.</p

Patient acceptance of universal screening for hepatitis C virus infection

<p>Abstract</p> <p>Background</p> <p>In the United States, about 70% of 2.9-3.7 million people with hepatitis C (HCV) are unaware of their infection. Although universal screening might be a cost-effective way to identify infections, prevent morbidity, and reduce transmission, few efforts have been made to determine patient opinions about new approaches to screening.</p> <p>Methods</p> <p>We surveyed 200 patients in August 2010 at five outpatient clinics of a major public urban medical center in Seattle, WA, with an 85.8% response rate.</p> <p>Results</p> <p>The sample was 55.3% women, median 47 years of age, and 56.3% white and 32.7% African or African-American; 9.5% and 2.5% reported testing positive for HCV and HIV, respectively. The vast majority of patients supported universal screening for HCV. When presented with three options for screening, 48% preferred universal testing without being informed that they were being tested or provided with negative results, 37% preferred testing with the chance to "opt-out" of being tested and without being provided with negative results, and 15% preferred testing based on clinician judgment. Results were similar for HIV screening.</p> <p>Conclusions</p> <p>Patients support universal screening for HCV, even if that screening involves testing without prior consent or the routine provision of negative test results. Current screening guidelines and procedures should be reconsidered in light of patient priorities.</p

Continuous pellet fueling experiments on D-III

A centrifuge pellet injector developed at ORNL was used to continuously fuel beam-heated limiter discharges in D-III. This injector was capable of producing and maintaining a high density neutral beam-heated plasma without auxilary gas fueling. Viewgraphs from the presentation are included